secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001437749-25-005802
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics posts Q4 net income $23.3M; FY 2024 BRIUMVI revenue $310M, guides 2025 global rev ~$540M
--------------------------------------------------------------------------------

- Q4 2024 BRIUMVI U.S. net revenue $103.6M; full year $310M, representing ~250% YoY growth.
- Net income of $23.3M in Q4 2024 vs net loss of $14.4M in Q4 2023; full year net income $23.4M.
- 2025 guidance: total global revenue ~$540M, including BRIUMVI U.S. net revenue ~$525M; operating expenses ~$300M.
- Cash, cash equivalents and investments $311M as of Dec 31, 2024; company expects sufficient funding from revenues.
- Pipeline: Phase 1 trials for subcutaneous ublituximab in MS and MG; licensed azer-cel CAR T for autoimmune indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925005802/0001437749-25-005802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925005802/tgtx20250225_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-005802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer